Lantheus Holdings Analyst Ratings
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Truist Securities Adjusts Price Target on Lantheus Holdings to $141 From $96, Maintains Buy Rating
Lantheus Buy Rating Affirmed Amid Favorable CMS Changes and Strong Market Position
B. Riley Raises Price Target on Lantheus Holdings to $105 From $99, Maintains Buy Rating
Strong Buy Rating for Lantheus Holdings Amidst Robust Financials and Growth Prospects
Lantheus Holdings Analyst Ratings
Analysts' Top Healthcare Picks: Lantheus (LNTH), Bicycle Therapeutics (BCYC)
Lantheus Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)
Buy Rating for Lantheus Holdings With Strong Growth and Acquisition Potential
Buy Rating on Lantheus Holdings Amid Overlooked Pylarify Growth and Market Expansion Opportunities
Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $82
Lantheus Holdings Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Lantheus (LNTH)
Lantheus Holdings: Strong Buy on Robust Q4 Earnings and Promising Growth Prospects
Lantheus Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)
Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Evolent Health (EVH)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA) and Lantheus (LNTH)